Terms: = Lymphoma AND REL, I-Rel, 5966, ENSG00000162924, C-Rel
288 results:
1. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract] [Full Text] [Related]
2. Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma.
Newsam AD; Coughlin CA; Trabolsi A; Schatz JH
Leuk Lymphoma; 2023 Dec; 64(14):2217-2224. PubMed ID: 37933565
[TBL] [Abstract] [Full Text] [Related]
3. Clonal evolution dissection reveals that a high MSI2 level promotes chemoresistance in T-cell acute lymphoblastic leukemia.
Zhang J; Duan Y; Wu P; Chang Y; Wang Y; Hu T; Liu C; Chen X; Zong S; Chen X; Wu Y; Jin L; Lan Y; Liu X; Cheng X; Ding F; Li T; Chen X; Guo Y; Chen Y; Yang W; Zhang L; Zou Y; Cheng T; Zhu X; Zhang Y
Blood; 2024 Jan; 143(4):320-335. PubMed ID: 37801708
[TBL] [Abstract] [Full Text] [Related]
4. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P; Bethge WA; Krämer I; Holtick U; von Tresckow B; Ayuk F; Penack O; Vucinic V; von Bonin M; Baldus C; Mougiakakos D; Wulf G; Schnetzke U; Stelljes M; Fante M; Schroers R; Kroeger N; Dreger P;
Transplant Cell Ther; 2023 Dec; 29(12):750-756. PubMed ID: 37709204
[TBL] [Abstract] [Full Text] [Related]
5. Conferone, a coumarin from
Rafatpanah H; Golizadeh M; Mahdifar M; Mahdavi S; Iranshahi M; Rassouli FB
Int J Immunopathol Pharmacol; 2023; 37():3946320231197592. PubMed ID: 37688389
[TBL] [Abstract] [Full Text] [Related]
6. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
7. Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell lymphoma in China: Evidence from a Cost-Effectiveness Analysis.
Wu W; Zhou Y; Wang Y; Keramat SA; Balasooriya NN; Zhao Z; Yang Y; Comans T; Dong H
Appl Health Econ Health Policy; 2023 Sep; 21(5):773-783. PubMed ID: 37356080
[TBL] [Abstract] [Full Text] [Related]
8. Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Sharman JP; Miranda P; Roos J; Emeribe U; Cai L; Liljas B; Gaitonde P
Leuk Lymphoma; 2023; 64(7):1243-1252. PubMed ID: 37221877
[TBL] [Abstract] [Full Text] [Related]
9. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with relapsed/Refractory Large B Cell lymphoma.
Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
[TBL] [Abstract] [Full Text] [Related]
10. Transformation of FL into DLBCL with a PMBL gene expression signature.
Loveday T; Duns G; Rimsza LM; Rech KL; Cook JR; Robetorye RS; Rosenthal AC; Ramsower CA; Yip TK; McKinney CL; Swerdlow SH; Bhavsar S; Steidl C; Gibson SE
Blood Adv; 2023 Mar; 7(6):893-899. PubMed ID: 36240289
[TBL] [Abstract] [Full Text] [Related]
11. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract] [Full Text] [Related]
12. Association of Single-Nucleotide Variants in the Human Leukocyte Antigen and Other Loci With Childhood Hodgkin lymphoma.
Chen C; Song N; Dong Q; Sun X; Mulder HL; Easton J; Zhang J; Yasui Y; Bhatia S; Armstrong GT; Wang H; Ness KK; Hudson MM; Robison LL; Wang Z
JAMA Netw Open; 2022 Aug; 5(8):e2225647. PubMed ID: 35939300
[TBL] [Abstract] [Full Text] [Related]
13. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia.
Ramos-Muntada M; Trincado JL; Blanco J; Bueno C; Rodríguez-Cortez VC; Bataller A; López-Millán B; Schwab C; Ortega M; Velasco P; Blanco ML; Nomdedeu J; Ramírez-Orellana M; Minguela A; Fuster JL; Cuatrecasas E; Camós M; Ballerini P; Escherich G; Boer J; DenBoer M; Hernández-Rivas JM; Calasanz MJ; Cazzaniga G; Harrison CJ; Menéndez P; Molina O
Mol Oncol; 2022 Aug; 16(16):2899-2919. PubMed ID: 35726693
[TBL] [Abstract] [Full Text] [Related]
14. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell lymphoma.
Munshi PN; Chen Y; Ahn KW; Awan FT; Cashen A; Shouse G; Shadman M; Shaughnessy P; Zurko J; Locke FL; Goodman AM; Bisneto JCV; Sauter C; Kharfan-Dabaja MA; Meyers G; Jaglowski S; Herrera A; Hamadani M
Transplant Cell Ther; 2022 Aug; 28(8):487.e1-487.e7. PubMed ID: 35609865
[TBL] [Abstract] [Full Text] [Related]
15. An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse.
Bartsch L; Schroeder MP; Hänzelmann S; Bastian L; Lázaro-Navarro J; Schlee C; Tanchez JO; Schulze V; Isaakidis K; Rieger MA; Gökbuget N; Eckert C; Serve H; Horstmann M; Schrappe M; Brüggemann M; Baldus CD; Neumann M
BMC Genom Data; 2022 Apr; 23(1):30. PubMed ID: 35436854
[TBL] [Abstract] [Full Text] [Related]
16. Ultrasound-guided lymph node sampling: accuracy of FNAC, end-cutting (Franseen), and side-cutting (Temno) needle biopsy techniques.
Yip SWY; Griffith JF; Chan RCK; Tong CSL; Hung EHY; Ng AWH; Lee RKL
Clin Radiol; 2022 Jun; 77(6):466-473. PubMed ID: 35410787
[TBL] [Abstract] [Full Text] [Related]
17. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
Kameda K; Kako S; Kim SW; Usui Y; Kato K; Fukuda T; Uchida N; Kobayashi H; Wakayama T; Sakaida E; Yano S; Imada K; Nara M; Ikeda T; Fuchida SI; Ishikawa J; Sugahara H; Kanda J; Kimura T; Ichinohe T; Atsuta Y; Kondo E
Leukemia; 2022 May; 36(5):1361-1370. PubMed ID: 35347237
[TBL] [Abstract] [Full Text] [Related]
18. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Ward JP; Berrien-Elliott MM; Gomez F; Luo J; Becker-Hapak M; Cashen AF; Wagner-Johnston ND; Maddocks K; Mosior M; Foster M; Krysiak K; Schmidt A; Skidmore ZL; Desai S; Watkins MP; Fischer A; Griffith M; Griffith OL; Fehniger TA; Bartlett NL
Blood; 2022 Mar; 139(13):1999-2010. PubMed ID: 34780623
[TBL] [Abstract] [Full Text] [Related]
19. Whole-genome landscape of adult T-cell leukemia/lymphoma.
Kogure Y; Kameda T; Koya J; Yoshimitsu M; Nosaka K; Yasunaga JI; Imaizumi Y; Watanabe M; Saito Y; Ito Y; McClure MB; Tabata M; Shingaki S; Yoshifuji K; Chiba K; Okada A; Kakiuchi N; Nannya Y; Kamiunten A; Tahira Y; Akizuki K; Sekine M; Shide K; Hidaka T; Kubuki Y; Kitanaka A; Hidaka M; Nakano N; Utsunomiya A; Sica RA; Acuna-Villaorduna A; Janakiram M; Shah U; Ramos JC; Shibata T; Takeuchi K; Takaori-Kondo A; Miyazaki Y; Matsuoka M; Ishitsuka K; Shiraishi Y; Miyano S; Ogawa S; Ye BH; Shimoda K; Kataoka K
Blood; 2022 Feb; 139(7):967-982. PubMed ID: 34695199
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma.
Alderuccio JP; Kuker RA; Barreto-Coelho P; Martinez BM; Miao F; Kwon D; Beitinjaneh A; Wang TP; Reis IM; Lossos IS; Moskowitz CH
Leuk Lymphoma; 2022 Jan; 63(1):43-53. PubMed ID: 34414842
[TBL] [Abstract] [Full Text] [Related]
[Next]
